In this study we demonstrate that the tumour–immune microenvironment (TME) of advanced high-grade serous ovarian cancer (HGSOC) is intrinsically heterogeneous and that chemotherapy induces local immune activation. Therefore, exploring new combination therapies and therapeutic targets based on a greater understanding of the TME has the potential to change the current treatment paradigm and improve clinical outcomes in patients with HGSOC.
